{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:48Z","timestamp":1784642808851,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009747","name":"Erik and Edith Fernstr\u00f6m Foundation","doi-asserted-by":"publisher","award":["2021-00209"],"award-info":[{"award-number":["2021-00209"]}],"id":[{"id":"10.13039\/501100009747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995882"],"award-info":[{"award-number":["R-995882"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995557"],"award-info":[{"award-number":["R-995557"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-993724"],"award-info":[{"award-number":["R-993724"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Research Council for Medicine and Health","award":["2023-02256"],"award-info":[{"award-number":["2023-02256"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2023-1055"],"award-info":[{"award-number":["FAI-2023-1055"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2023-1006"],"award-info":[{"award-number":["FAI-2023-1006"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2022-0877"],"award-info":[{"award-number":["FAI-2022-0877"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1000881"],"award-info":[{"award-number":["OLL-1000881"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Professor Nanna Svartz Foundation","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"name":"King Gustaf V and Queen Victoria\u2019s Freemasons\u2019 Foundation"},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024-43"],"award-info":[{"award-number":["2024-43"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024-49"],"award-info":[{"award-number":["2024-49"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2023-36"],"award-info":[{"award-number":["2023-36"]}]},{"DOI":"10.13039\/501100009806","name":"Ulla and Gustaf af Uggla Foundation","doi-asserted-by":"publisher","award":["2023-025029"],"award-info":[{"award-number":["2023-025029"]}],"id":[{"id":"10.13039\/501100009806","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region \u00d6sterg\u00f6tland ALF","award":["R\u00d6-981263"],"award-info":[{"award-number":["R\u00d6-981263"]}]},{"name":"Region Stockholm","award":["FoUI-1004114"],"award-info":[{"award-number":["FoUI-1004114"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Studies supporting therapeutic drug monitoring to biopharmaceuticals in SLE are scarce. We aimed to assess anti-drug antibody (ADA) occurrence in belimumab-treated SLE patients and associations between belimumab concentrations and clinical response, serological outcomes and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included 100 patients treated with intravenous belimumab. Clinical data and biological samples were collected at baseline and months 3, 6, 12 and 24. Belimumab levels were determined by quantitative sandwich ELISA, and ADA by an acid-dissociation radioimmunoassay. Clinical activity was evaluated with the SLEDAI-2000 (SLEDAI-2K), revised SLE activity measure (SLAM-R) and physician\u2019s global assessment (PhGA). Serological markers included C3, C4 and anti-dsDNA. We performed cross-sectional Spearman\u2019s rank correlation analyses, and longitudinal analyses using generalized estimating equations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Belimumab concentrations varied widely (median: 25.8; interquartile range [IQR]: 20.9\u201343.5\u2009\u03bcg\/ml) but were stable over time at the group level. Pre-existing ADA was detected in two patients, but no patient developed ADA during follow-up. Belimumab levels moderately correlated with SLEDAI-2K (\u03c1: \u22120.37; P = 0.003) and PhGA (\u03c1: \u22120.41; P = 0.005) at month 6, while longitudinal analysis revealed a very weak association with SLEDAI-2K (\u03b2: \u22120.10; SE: 0.05; P = 0.031) and a weak association with SLAM-R (\u03b2: \u22120.32; SE: 0.13; P = 0.014). Despite moderate correlations between belimumab levels and serological markers at month 6, there were no associations in longitudinal analysis. There was no relationship between belimumab levels and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Belimumab yielded no immunogenicity. Belimumab levels were modestly associated with clinical activity but not with serological activity or adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf128","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:13:16Z","timestamp":1741133596000},"page":"3797-3805","source":"Crossref","is-referenced-by-count":4,"title":["Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-1755","authenticated-orcid":false,"given":"Alvaro","family":"Gomez","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-4866","authenticated-orcid":false,"given":"Tomas","family":"Walhelm","sequence":"additional","affiliation":[{"name":"Division of Inflammation and Infection\/Rheumatology, Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris C","family":"Loeff","sequence":"additional","affiliation":[{"name":"R&D, Sanquin Diagnostic Services , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"J\u00f6nsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Rheumatology, Lund University, Sk\u00e5ne University Hospital , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"van den Broek","sequence":"additional","affiliation":[{"name":"R&D, Sanquin Diagnostic Services , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Rheumatology, Lund University, Sk\u00e5ne University Hospital , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"de Vries","sequence":"additional","affiliation":[{"name":"R&D, Sanquin Diagnostic Services , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"R&D, Sanquin Diagnostic Services , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Department of Immunopathology, Sanquin Research , Amsterdam,","place":["The Netherlands"]},{"name":"Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-2048","authenticated-orcid":false,"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[{"name":"Division of Inflammation and Infection\/Rheumatology, Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025052703525464400_keaf128-B1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramskold","year":"2019","journal-title":"EBioMedicine"},{"key":"2025052703525464400_keaf128-B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae364","article-title":"Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing","author":"Bang","year":"2024","journal-title":"Rheumatology"},{"key":"2025052703525464400_keaf128-B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703525464400_keaf128-B4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"2025052703525464400_keaf128-B5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"2025052703525464400_keaf128-B6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2025052703525464400_keaf128-B7","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025052703525464400_keaf128-B10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kead696","article-title":"Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients","volume":"64","author":"Altabas-Gonzalez","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703525464400_keaf128-B12","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025052703525464400_keaf128-B13","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703525464400_keaf128-B14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002216","article-title":"Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider","volume":"8","author":"Krieckaert","year":"2022","journal-title":"RMD Open"},{"key":"2025052703525464400_keaf128-B15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025052703525464400_keaf128-B16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2025052703525464400_keaf128-B17","doi-asserted-by":"crossref","first-page":"113717","DOI":"10.1016\/j.jim.2024.113717","article-title":"Belimumab concentration measurements using a homologous anti-idiotype immunoassay","volume":"532","author":"Loeff","year":"2024","journal-title":"J Immunol Methods"},{"key":"2025052703525464400_keaf128-B18","doi-asserted-by":"crossref","first-page":"115730","DOI":"10.1016\/j.jpba.2023.115730","article-title":"Determination of plasma concentration of belimumab by LC-MS\/MS: method development, validation, and clinical application","volume":"236","author":"Marin","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"2025052703525464400_keaf128-B19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard-2023-225023","article-title":"Low plasma belimumab levels as an indicator of poor adherence to belimumab in patients with systemic lupus erythematosus","volume":"83","author":"Trefond","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703525464400_keaf128-B20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001167","article-title":"Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report","volume":"11","author":"Blomjous","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2025052703525464400_keaf128-B21","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025052703525464400_keaf128-B24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14712598.2018.1494719","article-title":"Smoking reduces the efficacy of belimumab in mucocutaneous lupus","volume":"18","author":"Parodis","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025052703525464400_keaf128-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","article-title":"Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients","volume":"418","author":"Bloem","year":"2015","journal-title":"J Immunol Methods"},{"key":"2025052703525464400_keaf128-B26","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025052703525464400_keaf128-B27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1191\/096120301678646146","article-title":"Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus","volume":"10","author":"Bae","year":"2001","journal-title":"Lupus"},{"key":"2025052703525464400_keaf128-B28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B29","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","article-title":"De novo lupus nephritis during treatment with belimumab","volume":"60","author":"Parodis","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703525464400_keaf128-B30","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025052703525464400_keaf128-B31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jcph.104","article-title":"Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus","volume":"53","author":"Struemper","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2025052703525464400_keaf128-B32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40262-017-0586-5","article-title":"Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus","volume":"57","author":"Struemper","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2025052703525464400_keaf128-B33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","article-title":"Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"50","author":"Gehin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025052703525464400_keaf128-B34","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025052703525464400_keaf128-B35","first-page":"1934","article-title":"The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus","volume":"31","author":"Uribe","year":"2004","journal-title":"J Rheumatol"},{"key":"2025052703525464400_keaf128-B36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamadermatol.2022.4639","article-title":"Association of serum dupilumab levels at 16 weeks with treatment response and adverse effects in patients with atopic dermatitis: a prospective clinical cohort study from the BioDay registry","volume":"158","author":"Spekhorst","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025052703525464400_keaf128-B37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001985","article-title":"Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis","volume":"7","author":"Gehin","year":"2021","journal-title":"RMD Open"},{"key":"2025052703525464400_keaf128-B38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025052703525464400_keaf128-B39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B40","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025052703525464400_keaf128-B41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/rheumatology\/kead253","article-title":"Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials","volume":"63","author":"Gomez","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703525464400_keaf128-B42","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ekir.2023.06.021","article-title":"Effect of belimumab on preventing de novo renal lupus flares","volume":"8","author":"Parodis","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025052703525464400_keaf128-B43","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/rheumatology\/keae270","article-title":"Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?","volume":"64","author":"Rua-Figueroa","year":"2024","journal-title":"Rheumatology"},{"key":"2025052703525464400_keaf128-B44","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000638","article-title":"Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"9","author":"Sun","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025052703525464400_keaf128-B45","doi-asserted-by":"crossref","first-page":"108811","DOI":"10.1016\/j.intimp.2022.108811","article-title":"Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: a systematic review and meta-analysis of randomised controlled trials","volume":"109","author":"Xu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025052703525464400_keaf128-B46","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/ijms21103463","article-title":"Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus","volume":"21","author":"Parodis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025052703525464400_keaf128-B47","doi-asserted-by":"crossref","first-page":"911730","DOI":"10.3389\/fimmu.2022.911730","article-title":"Efficacy and safety of belimumab\/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"2025052703525464400_keaf128-B48","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies\u2014effects on treatment and immunogenicity","volume":"7","author":"van Schie","year":"2015","journal-title":"MAbs"},{"key":"2025052703525464400_keaf128-B49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Therapy"},{"key":"2025052703525464400_keaf128-B50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf128\/62244108\/keaf128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3797\/62244108\/keaf128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3797\/62244108\/keaf128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:53:07Z","timestamp":1748332387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3797\/8051133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf128","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,3]]}}}